Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 55Lymphoid 42Myeloid 19Plasma cell 6Other 5Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 2653Lymphoma, T-Cell, Cutaneous 479Skin Neoplasms 408Carcinoma, Non-Small-Cell Lung 377Mycosis Fungoides 330Neoplasms 319Keratosis, Actinic 300Sezary Syndrome 294Breast Neoplasms 285Neoplasm Metastasis 284Carcinoma, Renal Cell 280Lymphoma, Non-Hodgkin 276Lymphoma 264Carcinoma, Basal Cell 263Lymphoma, Large B-Cell, Diffuse 261Leukemia, Lymphocytic, Chronic, B-Cell 261Lymphoma, Follicular 259Hodgkin Disease 247Lymphoma, Mantle-Cell 245Lymphoma, B-Cell, Marginal Zone 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 243Uveal Melanoma 234Burkitt Lymphoma 233Lymphoma, Large-Cell, Immunoblastic 223Colorectal Neoplasms 196Lymphoma, Large-Cell, Anaplastic 190Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 186Ovarian Neoplasms 181Squamous Cell Carcinoma of Head and Neck 180Lung Neoplasms 179

Interventions

Rituximab 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bronchiolitis Obliterans Syndrome × Dermatologic × Clear all
NCT01994382 2022-04-05

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Alexion Pharmaceuticals, Inc.

Phase 1/2 Completed
260 enrolled 33 charts
DermatologicLymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡